Preclinical studies also demonstrated that MCL-1 inhibitors administered as monotherapy or in combination with BCL-2 inhibitors are highly effective in models of MM, AML, and additional hematologic malignancies22–26. The gene discussed is BCL2; the disease is acute myeloid leukemia.